MC2-32 Hidradenitis Suppurativa
(Oral)
About Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a debilitating, inflammatory disorder with a high, unmet medical need. It is characterized by chronic, painful nodules, abscesses and suppurating sinus tracts that in the most severe form cause significant scarring. Commonly affected body locations include the axillary, infra- and intermammary, inguinal, perineal and gluteal regions. Patients may experience pain, itching, malodour, and a burning sensation. For many patients the disease has a huge impact on their quality of life.
The female/male ratio is 3:1 in the Caucasian population although this may not be the same in the Asian and African population. HS occurs most commonly in the third and fourth decades of life although also children can have the disease. It can be difficult to diagnose HS and there is an average delay of 7-10 years between disease onset and diagnosis.
The disease mechanisms that cause HS are complex and not yet fully understood. However, HS is sometime described as an apocrinitis because blockage and inflammation in the apocrine glands around the hair follicles seems to be an important initial step in the disease pathogenesis. This results in increased expression of multiple pro-inflammatory cytokines and activation of a number of signaling pathways that together cause the skin manifestations seen in HS patients.
Treatment options are still limited and there remains a high unmet medical need.
Clinical Stage
Phase 2a completed.
Phase 2b in planning.
MC2-32
Active ingredient: HSP90 inhibitor
Indication: Hidradenitis Suppurativa
Pipeline
MC2-25 for Vulvar Lichen Sclerosus
About Vulvar Lichen Sclerosus
Vulvar Lichen Sclerosus (VLS) is a chronic, inflammatory, cutaneous disorder that can lead to scarring, impaired sexual function, and malignancy. It is a very debilitating disease with a severe impact on quality of life for both women and men in all ages. It is thought to be underdiagnosed and undertreated. If it is not treated, VLS is associated with a greater degree of pain, scarring and an elevated risk of cancer in the genital area.
While VLS can affect any area of the body of both males and females, it has a predilection for female anogenital epithelium. Extragenital involvement is reportedly present in 6% to 20% of patients.
The typical VLS patient is a woman around 50 years of age with external genital itch. The urge to itch and scratch is very strong and when aske patients often describe pain during sexual intercourse.
VLS is an autoimmune disease, and VLS patients have a higher risk of suffering from other autoimmune diseases. Despite a clear unmet medical need, there is no approved treatment for VLS in Europe or the US.
Aim of MC2-25
MC2 has made significant discoveries in the understanding of urea associated skin diseases, including Vulvar Lichen Sclerosus.
MC2-25 is an Iso-cyanate Scavenger addressing non-enzymatic posttranslational protein and amino acid modification (carbamylation) in the skin by iso-cyanate, a dissociation product of urea that is present in high concentrations in urine.
MC2-25 is formulated using our PAD Technology™ based cream to be highly tolerable, moisturizing and convenient to use as it quickly absorbs into the skin allowing patients to get on with their daily routines. MC2-25 is a novel treatment solution intended to significantly improve the daily quality of life of patients and provide a unique value proposition to multiple stakeholders such as patients, physicians, and society.
Clinical Stage
Phase 2
MC2-25 for Vulvar Lichen Sclerosus
Active ingredient: Iso-cyanate scavenger
Indication: Vulvar Lichen Sclerosus
Pipeline